Contains Solid Synthetic Resin Patents (Class 424/501)
  • Patent number: 10881609
    Abstract: The present disclosure generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon's space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: January 5, 2021
    Assignee: Retina Foundation Of The Southwest
    Inventor: Karl Csaky
  • Patent number: 10774122
    Abstract: The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 15, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Arul Chinnaiyan, Xiaoju Wang
  • Patent number: 10729702
    Abstract: Provided is a slow release composition to promote bone growth, the slow release composition comprising: an oxysterol encapsulated in a biodegradable polymer to control the release of the oxysterol. Methods of making and use are further provided.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: August 4, 2020
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: David S. Scher, Benjamin T. Reves, Roger E. Harrington, Susan J. Drapeau, Jerbrena C. Jacobs
  • Patent number: 10583091
    Abstract: This invention relates to amphiphile-polymer particles comprising obtaining a first solution comprising a water-insoluble polymer, a payload and a first amphiphile in a water-miscible solvent; mixing the first solution with an aqueous second solution to form an aqueous composition comprising a particle comprising a water-insoluble polymeric core comprising the water-insoluble polymer; the payload; and the first amphiphile.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: March 10, 2020
    Assignees: The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College
    Inventors: Jinjun Shi, Xi Zhu, Omid C. Farokhzad, Xiaoding Xu, Yanlan Liu, Aude Thiriot, Ulrich Von Andrian
  • Patent number: 10577554
    Abstract: Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 3, 2020
    Assignee: Children's Medical Center Corporation
    Inventors: John Kheir, Brian D. Polizzotti
  • Patent number: 10517910
    Abstract: The present disclosure relates to oncolytic viruses for use transcatheter arterial viroembolization methods. The present disclosure also provides composition with such oncolytic viruses in combination with a biocompatible microparticle or hydrophilic polymer gel agent suitable for active embolization. The present disclosure further provides methods of transcatheter arterial viroembolization using such oncolytic viruses and compositions preferably in a manner that debulks tumor.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 31, 2019
    Assignee: SILLAJEN, INC.
    Inventors: Tae Ho Hwang, Nam Hee Lee, Mong Cho, Ungbae Jeon, Doo Jin Byun
  • Patent number: 10517934
    Abstract: Compositions and methods for the treatment of skin disorders or disease are provided.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: December 31, 2019
    Assignee: ProTransit Nanotherapy, LLC
    Inventor: Vinod D. Labhasetwar
  • Patent number: 10463735
    Abstract: The present disclosure concerns a digital corneal crosslinking technology for adjusting the corneal curvature, comprising the following steps: administering in drops a composition comprising a photoinitiator compound to the corneal stromal of the subject, locally irradiating the corneal by utilizing digital micromirror device controlled by computer. The corneal curvature can be adjusted totally or locally. The invention also discloses an apparatus for the digital corneal crosslinking. The method and apparatus is minimum invasive and can be used to accurately and efficiently adjust the corneal curvature.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: November 5, 2019
    Assignee: ZHEJIANG UNIVERSITY
    Inventors: Tao Xie, Jingjun Wu, Qian Zhao, Limei Huang
  • Patent number: 10446782
    Abstract: A quantum dot device includes a first electrode and a second electrode facing each other, a quantum dot layer disposed between the first electrode and the second electrode and comprising a plurality of quantum dots, a first charge auxiliary layer disposed between the first electrode and the quantum dot layer and contacting the quantum dot layer, and a second charge auxiliary layer disposed between the second electrode and the quantum dot layer and contacting the quantum dot layer, wherein the plurality of quantum dots includes a quantum dot including an organic ligand on a surface thereof, the organic ligand including a hydrophilic functional group at a terminal end.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: October 15, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Moon Gyu Han, Dae Young Chung, Hongkyu Seo, Kwanghee Kim, Kun Su Park, Sujin Park, Eun Joo Jang
  • Patent number: 10434048
    Abstract: A topical sunscreen composition includes metal oxide sunscreen particles, polylactic acid, and a cosmetic carrier in which the metal oxide sunscreen particles and polylactic acid are dispersed. A method of preparing a topical sunscreen composition includes dispersing metal oxide sunscreen particles and polylactic acid in a cosmetic carrier. A method of protecting human skin from ultraviolet (UV) radiation includes applying to human skin a topical sunscreen composition including metal oxide sunscreen particles and polylactic acid dispersed in a cosmetic carrier.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: October 8, 2019
    Assignee: CYBERDERM LABORATORIES INC.
    Inventors: Denis Dudley, Thomas Heinar, Sara Dudley
  • Patent number: 10369537
    Abstract: This present invention provides a spray dryer for use in preparing particles for inhalation, the spray dryer comprising a multi-nozzle apparatus comprising multiple single nozzles suitable for use in preparing inhalation powders and with a drying gas flow rate greater than about 80 kg/h. Also provided is a method for scaling-up a spray drying process for preparing particles for inhalation from a smaller scale spray dryer to a larger scale spray dryer, relative in size to each other, the method comprising the use in the larger scale spray dryer of a multi-nozzle apparatus comprising single nozzles suitable for use in preparing inhalation powders, wherein the number of nozzles in the larger spray dryer is determined by the ratio of the drying gas flow rate of the larger scale spray dryer to the drying gas flow rate of the smaller scale spray dryer.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: August 6, 2019
    Assignee: Hovione Holding Limited
    Inventors: José Luis Santos, Luis Olival, Maria Palha, Filipa Maia, Filipe Neves
  • Patent number: 10369113
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 6, 2019
    Assignee: The Johns Hopkins University
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Patent number: 10364474
    Abstract: Disclosed are methods for identifying and/or classifying microbes using one or more single nucleotide polymorphisms (SNPs) in 16S ribosomal RNA (16S rRNA) of prokaryotes and/or one or more SNPs in 5.8S ribosomal RNA (5.8S rRNA) of eukaryotes. Also disclosed are probes, primers and kits that are useful in those methods. Methods for the diagnosis of sepsis based upon these SNPs are also disclosed.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: July 30, 2019
    Assignee: IMMUNEXPRESS PTY LTD
    Inventors: Richard Bruce Brandon, Flavia Huygens
  • Patent number: 10350222
    Abstract: An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: July 16, 2019
    Assignee: SpineThera
    Inventor: Jeffrey Missling
  • Patent number: 10328033
    Abstract: A nanostructured biocompatible wafer for drug delivery to a tissue. The wafer contains a tissue-reactive mucoadhesive polymer and a mesh formed of a plurality of polymer fibers. Also provided is a method for treating an ocular surface disease, disorder, or infection using the nanostructured biocompatible wafer. Additionally, an injectable sustained-release formulation for treating an ocular disorder is disclosed. The formulation includes a drug contained within a plurality of microparticles formed of a biodegradable polymer and are coated with a tissue-reactive compound. Further provided is a method for treating an ocular disorder by injecting the microparticulate sustained release formulation.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 25, 2019
    Assignee: Integral BioSystems LLC
    Inventors: Shikha P. Barman, Moli Liu, Koushik Barman, Kevin L. Ward, Brendan Hackett
  • Patent number: 10307373
    Abstract: Provided is a drug delivery system for control of initial burst of a drug. More particularly, there are provided a drug delivery formulation including: a granule containing a biodegradable polymer and a drug; and a temperature-sensitive hydrogel, and a method for preparing the same. The presently disclosed drug delivery formulation can be prepared via a relatively simple process and allows a drug to be released slowly at a constant rate without initial burst and thus maintains a constant blood level of the drug for a long period of time. Consequently, it is capable of preventing the initial burst of the existing injection-type drug delivery formulations and slow-release granules and providing a desired release profile, including sustained release with time.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: June 4, 2019
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Moon Suk Kim, Da Yeon Kim
  • Patent number: 10293044
    Abstract: Disclosed are compositions, kits, and methods for improving feed conversion rate in an animal in need thereof. The methods typically comprise administering orally to the animal a composition comprising biodegradable particles, the biodegradable particles comprising a polymer or a co-polymer comprising polylactide (PLA) and having an effective average diameter of 0.5-5 ?m. In the methods, the animal is administered a dose of the biodegradable particles that is effective for improving feed conversion rate in the animal in comparison to an animal that is not administered the composition.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: May 21, 2019
    Assignee: Auburn University
    Inventors: Bernhard Kaltenboeck, Ram B. Gupta, Erfan U. Chowdhury, Courtney A. Ober
  • Patent number: 10285939
    Abstract: The invention relates to compositions and methods that utilize polymeric nanoparticles to deliver a therapeutic compound to ocular cells or ocular tissue. Provided is a drug-loaded micelle comprising self-assembled amphiphilic biopolymers, such as hydrophobically modified nucleic acids or polypeptides, for use as ophthalmic drug delivery system. Also provided are ophthalmic compositions and methods for preventing or treating an ophthalmic disease.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: May 14, 2019
    Assignee: Eberhard Karls Universität Tübingen Medizinische Fakultät
    Inventors: Andreas Herrmann, Jan Willem De Vries, Martin Stephan Spitzer, Sven Oliver Schnichels
  • Patent number: 10286033
    Abstract: The invention provides methods and compositions for use of desmopressin in combination with an alpha-adrenergic receptor antagonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 14, 2019
    Assignee: Serenity Pharmaceuticals, LLC
    Inventors: Seymour H. Fein, Linda Cheng, Maria Cheng, Samuel Herschkowitz
  • Patent number: 10258563
    Abstract: The present invention includes a construct that comprises at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention also includes a pharmaceutical composition comprising a construct comprising at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention further includes a method of imaging a tissue or organ in a subject, a method of delivering a therapeutic cargo to a tissue or organ in a subject, and a method of treating a disease or disorder in a subject.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: April 16, 2019
    Assignee: Drexel University
    Inventors: Steven P. Wrenn, Stephen Dicker
  • Patent number: 10231937
    Abstract: An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: March 19, 2019
    Assignee: The Trustees of Princeton University
    Inventors: Robert F. Pagels, Robert K. Prud'homme
  • Patent number: 10221272
    Abstract: A method of forming a patterned polymer layer on a substrate and a substrate having a polymer layer formed by the method. The method includes providing a substrate comprising a first surface having a first surface energy and a pattern located on the substrate forming a second surface having a second, lower surface energy than the first surface, and selectively depositing a polymeric layer onto the first surface using a monomer material in an initiated chemical vapor deposition process, wherein the initiated chemical vapor deposition process is operated under supersaturation conditions during the deposition process.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: March 5, 2019
    Assignee: DREXEL UNIVERSITY
    Inventors: Kenneth Ka Shun Lau, Sruthi Janakiraman, Chia-Yun Hsieh
  • Patent number: 10195309
    Abstract: A composition comprising polymer particles and a carrier, wherein the polymer particles are a mixture of at least a first polymer and a second polymer, wherein the first polymer is at least partially soluble or dispersible in the carrier, and wherein the polymer particles are arranged such that they can join together to form a scaffold of polymer particles, and wherein the composition is administrable to a human or non-human animal.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: February 5, 2019
    Assignee: LOCATE THERAPEUTICS LIMITED
    Inventors: Patrick Ginty, Robin Andrew Quirk, Kevin Morris Shakesheff
  • Patent number: 10188658
    Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimized pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: January 29, 2019
    Assignee: WisTa Laboratories Ltd.
    Inventors: Claude Michel Wischik, Damon Jude Wischik, John Mervyn David Storey, Charles Robert Harrington
  • Patent number: 10179190
    Abstract: Methods of treating tissue of a patient, e.g., tissue of an organ such that the bladder, are described. The methods may comprise inserting a medical device within the bladder; and injecting a composition to separate a first layer of tissue from a second layer of tissue. The composition may comprise at least one polysaccharide compound having a concentration ranging from approximately 0.05% to approximately 25% by weight, with respect to the total weight of the composition. The composition may at least partially separate the first layer of tissue from the second layer of tissue. At least one of the first layer of tissue or the second layer of tissue may be a detrusor muscle tissue.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 15, 2019
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Sandra Nagale, David Shreeve, Mark Boden, Jonathan Zoll, Timothy Harrah, Steven Kangas, Kasyap Seethamraju, Deanna Cavallaro, Martin Phelan
  • Patent number: 10179834
    Abstract: The disclosure relates to biodegradable polyether network polymers crosslinked via ester linkages, to substrates, implants and scaffolds comprising the biodegradable polyether network polymers, to methods for preparing such network polymers, implants and scaffolds, and to methods of using substrates, implants and scaffolds comprising the network polymers, particularly for culturing cells and regenerating tissue.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: January 15, 2019
    Assignee: The University of Melbourne
    Inventors: Anton Blencowe, Berkay Ozcelik, Greg Guanghua Qiao
  • Patent number: 10159743
    Abstract: Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: December 25, 2018
    Assignee: The Johns Hopkins University
    Inventors: Jie Fu, Peter A. Campochiaro, Justin Scot Hanes
  • Patent number: 10137088
    Abstract: Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer—EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: November 27, 2018
    Assignee: Pfizer Inc.
    Inventors: Stephen E. Zale, Kevin Andrew McDonnell, Allen Thomas Horhota
  • Patent number: 10076496
    Abstract: The present invention provides organic nanoparticles that include a molecule having a Log P value of about 3 or above, an amphiphilic diblock copolymer or a surfactant, and a pharmaceutically-acceptable hydrophilic polymer. The present invention also provides methods of making these nanoparticles, e.g., by flash nanoprecipitation, with control over particle size and surface properties. The methods of the present invention provide a means for co-precipitating a water-insoluble compound with an amphiphilic stabilizer within a few milliseconds. The nanoparticles of the present invention exhibit high drug loading, e.g., 50% w/w, and can be produced with a mean particle size less than 200 nm and with a narrow particle size distribution.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: September 18, 2018
    Assignee: The Chinese University of Hong Kong
    Inventors: Albert Hee Lum Chow, Shing Fung Chow, Xin Ran Zhang, Ka Yee Wan, Kwok Kin Cheng, Lawrence William Baum
  • Patent number: 10064819
    Abstract: Devices, systems, and methods for delivery of an active agent into the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: September 4, 2018
    Assignee: University of Utah Research Foundation
    Inventors: Balamurali K. Ambati, Bruce K. Gale, Srinivas Rao Chennamaneni
  • Patent number: 10004790
    Abstract: A method of transdermal delivery of a vaccine, comprising preparing microparticles of encapsulated vaccine by spray drying a mixture of the vaccine and at least one polymer, and injecting the microparticles transdermally using a microneedle delivery apparatus.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: June 26, 2018
    Assignee: THE CORPORATION OF MERCER UNIVERSITY
    Inventor: Martin J. D'Souza
  • Patent number: 9919052
    Abstract: Polyurethane microparticles are derived from structural units comprising poly(alkylene oxide) moieties, caprolactone moieties and urethane moieties. The microparticles may include an active agent and have a particle size from 0.1 to 100 microns. Microparticles for injection have a particle size of 15 to 80 microns; for use as a aerosol 1 to 3 microns; and for intraocular use 0.02 to 2 microns. Dispersivity is in the range 1 to 3.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: March 20, 2018
    Assignee: Ferring B.V.
    Inventors: Alistair Ross, Jennifer S. Law, Fiona E. McInnes
  • Patent number: 9885808
    Abstract: Coating with photochromic properties, method for producing said coating and use thereof applicable to optical articles and glazed surfaces. The coating is formed by the combination of the following three elements: (1) a polymeric matrix, which is typically rigid and deposited on the surface of interest; (2) hollow, sealed micro- and/or nanocapsules dispersed within said matrix; and (3) solutions of photochromic compounds (chosen from a group comprising spirooxazine, azobenzenes or chromenes) in a liquid solvent that does not react (with the photochromic compound and with the capsule wall), which are encapsulated inside said micro- or nanocapsules.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: February 6, 2018
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS(CSIC)
    Inventors: Jordi Hernando Campos, Claudio Roscini, Nuria Alexandra Vazquez Mera, Daniel Ruiz Molina
  • Patent number: 9884146
    Abstract: The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: February 6, 2018
    Assignee: Interface Biologics Inc.
    Inventors: Sanjoy Mullick, Weilun Chang, Hanje Chen, Mark A. Steedman, Roseita Esfand
  • Patent number: 9850531
    Abstract: The present invention relates to a method for protecting and. recovering nucleic acids. This method may be applied in a verification method of products using molecular code systems or it may be applied in a storage method for nucleic acids. The invention further provides specific particles, their use in secure marking; products suitable for such verification method, to processes for manufacturing such products and methods for reading the information.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: December 26, 2017
    Assignee: ETH Zurich
    Inventors: Robert N. Grass, Wendelin Jan Stark
  • Patent number: 9801829
    Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of making nanostructures (e.g., nanoparticles, nanofibers), systems for making nanostructures, and the like.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 31, 2017
    Assignees: University of Florida Research Foundation, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Peng Guo, Charles R. Marin, Yaping Zhao, Richard N. Zare
  • Patent number: 9770537
    Abstract: The invention provides therapeutic particulates including a macrolide, such as rapamycin, in solid state crystalline form, having a size of 20?m or less, or 10?m or less. The particulates are formed in one method by preparing a composition with a macrolide and first (e.g., xylene) and second (e.g., an alcohol, acetone, or acetonitrile) solvents. In the composition a maximum solubility for the macrolide that is greater than a maximum solubility of the macrolide dissolved in either the first or second solvent individually. The first and second solvents are then evaporated from the composition to provide the macrolide particulates. In another method, the particulates can be formed by a method including sonication and stirring/evaporation steps, and the particulates can be obtained from a supersaturated solution, formed during the process.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: September 26, 2017
    Assignee: SURMODICS, INC.
    Inventors: Joram Slager, Aleksey V. Kurdyumov, Toni M. Heyer
  • Patent number: 9757480
    Abstract: A radiopaque particulate material one or more of SiO2, TiO2, La2O3, Na2O and MgO and useful for embolization which optionally includes therapeutic components that are released in vivo.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: September 12, 2017
    Assignee: ABK Biomedical Incorporated
    Inventors: Robert J. Abraham, Sharon Kehoe, Daniel Boyd
  • Patent number: 9597436
    Abstract: Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: March 21, 2017
    Assignees: Osaka University, Nipro Corporation, Ono Pharmaceutical Co., Ltd.
    Inventors: Yoshiki Sawa, Shigeru Miyagawa, Satsuki Fukushima, Atsuhiro Saito, Yoshiki Sakai, Kazuhisa Matsuda, Takayuki Maruyama
  • Patent number: 9561284
    Abstract: A pharmaceutical composition includes a block copolymer having a hydrophilic segment, a hydrophobic segment, and a boronic acid compound bound to a side chain of the hydrophobic segment via a linker moiety that includes a heterocyclic structure. The heterocyclic structure contains a cyclic skeleton that includes a boron atom of the boronic acid compound, one or two atom(s) X bound to the boron atom and selected from an oxygen atom and a nitrogen atom, and one or two carbon atom(s) (respectively) bound to the atom(s) X. The block copolymer further includes at least one organic group bound to the carbon atom(s). The organic group(s) contain(s) an aromatic group or cyclic alkyl group that sterically protects a boronic acid ester bond and/or a boron amide bond resulting from bonding between the boron atom and the atom(s) X.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: February 7, 2017
    Assignee: NANOCARRIER CO., LTD.
    Inventors: Hiroyuki Saito, Katsutoshi Kobayashi, Ryosuke Tanaka, Mitsunori Harada, Yasuki Kato
  • Patent number: 9504659
    Abstract: The invention relates to a thermoreversible oil-in-water emulsion comprising: a TLR4 agonist, the chemical structure of which does not comprise a sugar ring, squalene, a nonionic surfactant belonging to the polyoxyethylene alkyl ether chemical group, a hydrophilic surfactant, an aqueous solvent, and which shows immunostimulating properties.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: November 29, 2016
    Assignee: Sanofi Pasteur SA
    Inventors: Marie-Françoise Klucker, Jean Haensler, Patricia Probeck-Quelleec, Pascal Chaux
  • Patent number: 9452155
    Abstract: This invention relates to a composition, including penethamate (PNT) or a pharmaceutical equivalent thereof; and triacetin.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: September 27, 2016
    Assignee: BAYER NEW ZEALAND LTD
    Inventors: Fadil Al Alawi, Karthigeyan Nanjan
  • Patent number: 9415123
    Abstract: Provided herein are nanobubbles designed for use in ultrasound-mediated ablation of cancer cells. The nanobubbles undergo ultrasound-mediated cavitation at an ablation threshold which is significantly decreased, relative to standard ultrasound-mediated treatment of cancer cells. In exemplary embodiments, the nanobubbles comprise an amphiphilic ABC triblock copolymer, wherein block A comprises a hydrophilic polymer, block B comprises a crosslinking polymer, and block C comprises a hydrophobic copolymer comprising (i) methyl methacrylate (MMA) and (ii) a fluorinated monomer, wherein the fluorinated monomer is present in the hydrophobic copolymer of block C at 25 mole percent or less. Related treatment and diagnostic methods, as well as materials relating to the nanobubbles are provided herein. Methods of making a random copolymer are furthermore provided herein.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: August 16, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Mohamed El-Sayed, Yasemin Yuksel Durmaz
  • Patent number: 9393295
    Abstract: In various aspects of the present invention, nanoparticle compositions are provided which comprise (a) nanoparticles comprising at least one biodegradable polymer and (b) at least one pharmaceutical associated with the nanoparticles. In other aspects of the present invention, methods of forming nanoparticles compositions are provided, which comprise contacting a first liquid that comprises one or more biodegradable polymers dissolved in a first solvent with a second liquid that comprises a second solvent which is miscible with the first solvent while being a non-solvent for the one or more biodegradable polymers, such that nanoparticles are formed.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: July 19, 2016
    Assignee: Novartis AG
    Inventors: Aravind Chakrapani, Manmohan Singh, Derek O'Hagan
  • Patent number: 9393310
    Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: July 19, 2016
    Assignee: BIND Therapeutics, Inc.
    Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
  • Patent number: 9267002
    Abstract: A method of making a hyperbranched amphiphilic polyester compound includes drying under vacuum a mixture of 2-(4-hydroxybutyl)-malonic acid and p-toluene sulphonic acid as catalyst. The vacuum is then released with a dry inert gas after drying. The dried mixture is heated under the inert gas at a temperature sufficient for polymerization. The inert gas is evacuated while continuing to heat the mixture. The formed polymer is then dissolved in dimethylformamide and precipitated out by adding methanol. Modifications of the method yield nanoparticles of polyesters having properties suited for coencapsulating fluorescent dyes together with therapeutic drugs, resulting in theranostic nanoparticles, that is, nanoparticles useful in both therapeutic treatments and diagnostic methods.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: February 23, 2016
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: J. Manuel Perez, Santimukul Santra
  • Patent number: 9226997
    Abstract: The present invention aims to provide a biodegradable particle capable of being molded without an aggregation or cohesion of the particles, capable of being carried or injected without clogging by an aggregation in a micro diameter tube such as of a catheter, needle or syringe mainly used in pharmaceutical and medical applications of which inner diameter is smaller than the particle size or in a blood vessel and capable of being smoothly degraded in a specified period of time so that degraded component can finally be absorbed or discharged in vitro. As means for solving the problem, the present invention provides a biodegradable particle characterized in that a compressive modulus of the particle in water saturated state is 10 MPa or less.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: January 5, 2016
    Assignee: Toray Industries, Inc.
    Inventors: Kazuhiro Tanahashi, Megumi Nakanishi
  • Patent number: 9205105
    Abstract: A method of treating pain involves administering to a human in need of such treatment a therapeutically effective amount of hyaluronic acid. In some embodiments, the hyaluronic acid is a non-avian based non-cross linked hyaluronic acid configured to treat post-traumatic and degenerative joint disorders. In some embodiments, the hyaluronic acid is cross linked hyaluronic acid.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: December 8, 2015
    Inventor: John Ascencion Campa, III
  • Patent number: 9205046
    Abstract: The present invention relates to a composite hydrogel comprising a blend of an aqueous solution of an anionic polysaccharide or a derivative thereof, such as hyaluronan (also commonly referred to as hyaluronic acid) or a derivative thereof and an aqueous solution of methylcellulose or another water soluble cellulose derivative thereof, having dispersed polymeric particles, such as polymeric hydrophobic particles therein selected from micro particles and nanoparticles, and wherein the stability of the hydrogel is enhanced relative to the stability of the hydrogel alone. The polymeric particles may contain at least one therapeutic agent, in which case each therapeutic agent exhibits a linear sustained release rate that can be tuned or altered by selecting the appropriate polymer formulation of the micro particles and/or nanoparticles.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: December 8, 2015
    Assignee: The Governing Council of the University of Toronto
    Inventors: Molly S. Shoichet, M. Douglas Baumann, Catherine Elizabeth Kang
  • Patent number: 9193836
    Abstract: A process for producing fine particles of polyamide-imide resin includes a dissolution step and a precipitation step wherein the dissolution step is selected from steps (a1) and (b1); (a1) polyamide-imide resin is dissolved in an organic solvent to prepare a polyamide-imide resin solution A1 having a polyamide-imide resin content of less than 5 mass %; and (b1) polyamide-imide resin is dissolved in an organic solvent to prepare a polyamide-imide resin solution B1 having a polyamide-imide resin content of less than 10 mass %, and the precipitation step is selected from (a2) the polyamide-imide resin solution A1 is added to a solvent that is virtually free from surface active agents and able to precipitate fine particles of the polyamide-imide resin to cause precipitation of fine particles of the polyamide-imide resin, and (b2) the polyamide-imide resin solution B1 is subjected to flash crystallization to cause precipitation of fine particles of the polyamide-imide resin.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: November 24, 2015
    Assignee: Toray Industries, Inc.
    Inventors: Hiroaki Akasaka, Takae Ono, Toshiya Takahashi